Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 929 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
30
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
64
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Conditions
Advanced HR+/HER2- Breast Cancer
Interventions
IEV407, Fulvestrant, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
New Haven, Connecticut • Kansas City, Kansas • Dallas, Texas
Conditions
Breast Cancer
Interventions
EG12014, Herceptin
Drug
Lead sponsor
EirGenix, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Farmington Hills, Michigan • Canton, Ohio
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy, Discussion, Survey Administration
Procedure · Device · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Conditions
HER2 Positive Breast Cancer
Interventions
tucatinib, capecitabine, trastuzumab, placebo
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Conditions
Advanced Breast Cancer
Interventions
Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
57
States / cities
Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Conditions
Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen, Mammogram, Magnetic Resonance Imaging, Dual X-ray Absorptiometry, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
728
States / cities
Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Conditions
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Interventions
IAM1363, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab, Oral treatment with IAM1363 capsules or tablets, administered in combination with T-Dxd, Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed
Drug
Lead sponsor
Iambic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 23 more
Conditions
Breast Neoplasms
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Encinitas, California • Santa Monica, California + 3 more
Not listed No phase listed Observational

NSABP Biospecimen Discovery Project

NCT01850628
Conditions
Breast Cancer
Interventions
Paclitaxel, trastuzumab, pertuzumab
Drug · Biological
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New York, New York + 2 more
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

NCT00791037
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, leukapheresis, ex vivo-expanded HER2-specific T cells, cyclophosphamide, sargramostim, laboratory biomarker analysis
Biological · Procedure · Drug + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer
Interventions
Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
223
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
Conditions
HER2-positive Breast Cancer, Breast Cancer
Interventions
Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
34
States / cities
Long Beach, California • Los Alamitos, California • Los Angeles, California + 29 more
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancers With HER2 Expression
Interventions
BAY2701439
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more